MiR-30e-3p Influences Tumor Phenotype through

Animals Antineoplastic Agents / pharmacology Binding Sites Carcinogens Carcinoma, Hepatocellular / drug therapy Cell Proliferation Cohort Studies Diethylnitrosamine Disease Models, Animal Down-Regulation Drug Resistance, Neoplasm Epithelial Cell Adhesion Molecule / metabolism Gene Silencing Genes, Tumor Suppressor Genes, p53 / genetics Hep G2 Cells Heterografts Humans Liver Neoplasms / drug therapy MicroRNAs / metabolism Mutation Neoplasm Invasiveness Neoplasm Proteins / genetics Neoplastic Stem Cells PTEN Phosphohydrolase / metabolism Phenotype Proliferating Cell Nuclear Antigen / metabolism Proto-Oncogene Proteins c-mdm2 / genetics Rats Sorafenib / pharmacology Tissue Array Analysis Tumor Suppressor Protein p53 / genetics

Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 04 2020
Historique:
received: 06 02 2019
revised: 29 06 2019
accepted: 28 01 2020
pubmed: 6 2 2020
medline: 21 10 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

The molecular background of hepatocellular carcinoma (HCC) is highly heterogeneous, and biomarkers predicting response to treatments are an unmet clinical need. We investigated miR-30e-3p contribution to HCC phenotype and response to sorafenib, as well as the mutual modulation of

Identifiants

DOI: 10.1158/0008-5472.CAN-19-0472 PMID: 32015093
pubmed: 32015093
pii: 0008-5472.CAN-19-0472
doi: 10.1158/0008-5472.CAN-19-0472
doi:

Substances chimiques

Antineoplastic Agents 0
Carcinogens 0
EPCAM protein, human 0
Epithelial Cell Adhesion Molecule 0
MIRN30b microRNA, human 0
MicroRNAs 0
Neoplasm Proteins 0
Proliferating Cell Nuclear Antigen 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0
p27 antigen 0
Diethylnitrosamine 3IQ78TTX1A
Sorafenib 9ZOQ3TZI87
MDM2 protein, human EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1720-1734

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Laura Gramantieri (L)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy. francesca.fornari2@unibo.it laura.gramantieri@aosp.bo.it.

Daniela Pollutri (D)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Martina Gagliardi (M)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Catia Giovannini (C)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Santina Quarta (S)

Department of Medicine, University of Padua, Padua, Italy.

Manuela Ferracin (M)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Andrea Casadei-Gardini (A)

Division of Oncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy.

Elisa Callegari (E)

Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.

Sabrina De Carolis (S)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Sara Marinelli (S)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Francesca Benevento (F)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Francesco Vasuri (F)

Pathology Unit, St.Orsola-Malpighi University Hospital, Bologna, Italy.

Matteo Ravaioli (M)

General Surgery and Transplant Unit, St.Orsola-Malpighi University Hospital, Bologna, Italy.

Matteo Cescon (M)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
General Surgery and Transplant Unit, St.Orsola-Malpighi University Hospital, Bologna, Italy.

Fabio Piscaglia (F)

Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
ORCID: 0000-0001-8264-1845

Massimo Negrini (M)

Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
ORCID: 0000-0002-0007-1920

Luigi Bolondi (L)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Francesca Fornari (F)

Center for Applied Biomedical Research, St.Orsola-Malpighi University Hospital, Bologna, Italy. francesca.fornari2@unibo.it laura.gramantieri@aosp.bo.it.
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
ORCID: 0000-0002-4302-4411

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Cancérogènes › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › Carcinome hépatocellulaire › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Composés chimiques organiques › Composés nitrosés › Nitrosamines › N-Éthyl-N-nitroso-éthanamine › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation négative › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Molécules d'adhérence cellulaire › Molécule d'adhérence des cellules épithéliales › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › Gènes p53 › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Cellules › Cellules épithéliales › Hépatocytes › Cellules HepG2 › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Régions du corps › Transplants › Hétérogreffes › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies du foie › Tumeurs du foie › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Invasion tumorale › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches tumorales › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines suppresseurs de tumeurs › Phosphohydrolase PTEN › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Phénomènes génétiques › Phénotype › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène nucléaire de prolifération cellulaire › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéines proto-oncogènes c-mdm2 › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Acides nicotiniques › Nicotinamide › Sorafénib › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Techniques d'investigation › Procédures d'analyse sur micropuce › Analyse sur microréseau › Analyse sur puce à tissus › MiR-30e-3p Influences Tumor Phenotype through
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › MiR-30e-3p Influences Tumor Phenotype through